Strong competition from generic drugmakers depressed sales at GlaxoSmithKline, although the pharmaceutical group raised its dividend, saying that it saw clear areas of strength in consumer healthcare and especially in vaccines.

Consumer healthcare sales rose 9 per cent in the three months to the end of June, helped by the European launch of Alli, an over-the-counter anti-obesity drug.